Can beta-lactamase inhibitor combinations keep pace with resistant urinary tract infections?

What’s changed: older combos are losing ground, but new ones are stepping in

For years, the go-to answer for resistant UTIs was a beta-lactamase inhibitor combo like amoxicillin-clavulanate. But the picture has shifted. In a 2024 study from Bangladesh, resistance to amoxicillin-clavulanate among UTI pathogens hit 93.7% [3]. That’s a staggering number—it means the drug is nearly useless in that setting. Similarly, a 2023 pediatric study found 39.4% of ESBL-producing (extended-spectrum beta-lactamase) uropathogens were resistant to amoxicillin/clavulanic acid [5]. These aren’t isolated anecdotes; they reflect a global trend of rising resistance to older combinations.

The good news: newer beta-lactamase inhibitor combinations have been approved in the last couple of years specifically to tackle these resistant bugs. Cefepime/enmetazobactam is now approved for complicated UTIs, including pyelonephritis, and targets ESBL-producing Enterobacterales and Pseudomonas aeruginosa [7]. Aztreonam/avibactam goes even further, covering carbapenem-resistant Enterobacterales—the toughest cases—and is also approved for complicated UTIs [7]. So while the old workhorses are failing, the pipeline is delivering new tools.

When older combos still work—and when they don’t

Even when lab tests say a bug is resistant, the drug might still work in the body. A 2022 study of children hospitalized for UTIs found that 47.2% of those on discordant empirical therapy (meaning the antibiotic was resistant in vitro) still had clinical failure—but that also means over half improved despite the lab result [1]. So in-vitro resistance isn’t an automatic death sentence. However, the same study found that treatment with penicillin plus beta-lactamase inhibitors (like amoxicillin-clavulanate) had a higher failure rate (57.1%) compared to other discordant antibiotics, and it was an independent risk factor for failure [1].

The catch is that success depends heavily on the patient and the bug. Risk factors for failure include recurrent UTIs, recent antibiotic use, and Pseudomonas aeruginosa infections [1]. In older adults, male gender, recurrent UTIs, and secondary bacteremia are associated with ESBL-producing infections [2]. So for a frail elderly man with a history of recurrent UTIs, relying on an older combo is risky—carbapenems may be prioritized [2]. For a healthy child with a first UTI, the odds are better, but you still need to watch for red flags.

What this means for treatment decisions

The bottom line: don’t assume a beta-lactamase inhibitor combo will work just because it used to. Local resistance patterns matter enormously. In Pakistan, resistance to ceftriaxone (a third-generation cephalosporin) was 66.7% in E. coli, and ciprofloxacin resistance was 51.8% [4]. In Bangladesh, carbapenem resistance (imipenem) was 72.5% in UTI pathogens, and 25.4% carried metallo-beta-lactamase genes [3]. These numbers should guide empirical choices—if you’re in a high-resistance area, you may need to start with a carbapenem or a newer combo.

The newer combinations are not a silver bullet either. They are powerful, but they should be used judiciously to preserve their efficacy. The 2025 review on complicated UTIs stresses the need for antimicrobial stewardship and targeted therapy based on local resistance profiles [6]. So the answer to the question is: yes, beta-lactamase inhibitor combinations can keep pace, but only if you choose the right one for the right patient, and only if we use them wisely.

About These Sources

This answer is built on 7 peer-reviewed studies — published from 2022 to 2025, 4 from 2024 or later, 2 in Q1 journals, collectively cited 84 times — selected as the most relevant from 8 studies that passed quality screening, drawn from 42 papers retrieved from a database of over 500 million.

Sources used in this answer

Related research questions